• 1
    Patel S, Lyons AR, Hosking DJ 1993 Drugs used in the treatment of metabolic bone disease: Clinical pharmacology and therapeutic use. Drugs 46:594617.
  • 2
    Azria M, Copp DH, Zanelli JM 1995 Twenty-five years of salmon calcitonin: From synthesis to therapeutic use. Calcif Tissue Int 57:405408.
  • 3
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med 109:267276.
  • 4
    Kleerekoper M, Schein JR 2001 Comparative safety of bone remodeling agents with a focus on osteoporosis therapies. J Clin Pharmacol 41:239250.
  • 5
    Avramides A, Flores A, DeRose J, Wallach S 1976 Paget's disease of the bone: Observations after cessation of long-term synthetic salmon calcitonin treatment. J Clin Endocrinol Metab 42:459463.
  • 6
    Lee YH, Leesman GD, Makhey V, Yu H, Hu P, Perry B, Sutyak JP, Wagner EJ, Falzone LM, Stern W, Sinko PJ 2000 Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs. Eur J Pharm Biopharm 50:205211.
  • 7
    Antonin KH, Saano V, Bieck P, Hastewell J, Fox R, Lowe P, Mackay M 1992 Colonic absorption of human calcitonin in man. Clin Sci 83:627631.
  • 8
    Beglinger C, Born W, Muff R, Drewe J, Dreyfuss JL, Bock A, Mackay M, Fischer JA 1992 Intracolonic bioavailability of human calcitonin in man. Eur J Clin Pharmacol 43:527531.
  • 9
    Habener JF, Singer FR, Neer RM, Deftos LJ, Potts JT 1971 Metabolism of salmon and porcine calcitonin: An explanation for the increased potency of salmon calcitonin. In: Talmage RV, Munson PL (eds.) Calcium, Parathyroid Hormone and the Calcitonins. Proceedings of the Fourth Parathyroid Conference, Chapel Hill. Excerpta Medica, Amsterdam, The Netherlands, pp. 152156.
  • 10
    Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sorensen OH 1991 Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302307.
  • 11
    Ellerington MC, Hillard TC, Whitcroft SIJ, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC 1996 Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 59:611.
  • 12
    Overgaard K, Hansen MA, Dirksen KL, Christiansen C 1992 Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 51:184188.
  • 13
    Kollerup G, Hermann AP, Brixen K, Lindblad BE, Mosekilde L, Sorensen OH 1994 Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 54:1215.
  • 14
    Combe B, Cohen C, Aubin F 1997 Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 61:1015.
  • 15
    Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burckhardt P 1987 The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 41:252258.
  • 16
    Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G, Sorensen OH 1993 Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 53:232236.
  • 17
    Lee YH, Sinko PJ 2000 Oral delivery of salmon calcitonin. Adv Drug Deliv Rev 42:225238.
  • 18
    Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, De Deuxchaisnes CN 1994 Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 55:7173.
  • 19
    Torres-Lugo M, Peppas NA 2000 Transmucosal delivery systems for calcitonin: A review. Biomaterials 21:11911196.
  • 20
    Sakuma S, Hayashi M, Akashi M 2001 Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 47:2137.
  • 21
    Millest AJ, Evans JR, Young JJ, Johnstone D 1993 Sustained release of salmon calcitonin in vivo from lactide-glycolide copolymer depots. Calcif Tissue Int 52:361364.
  • 22
    New R, Littlewood G, Guard P, Browning I, Hotten P 1997 Intestinal delivery of calcitonin in pig. Int J Pharm 156:18.
  • 23
    Dogru ST, Calis S, Öner F 2000 Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: In vitro-in vivo evaluation. J Clin Pharm Ther 25:435443.
  • 24
    Lee YH, Perry BA, Sutyak JP, Stern W, Sinko PJ 2000 Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs. Pharmacol Res 17:284290.
  • 25
    Stern W, Gilligan JP 2000 Oral peptide pharmaceutical products. US patent 6086918.
  • 26
    Clark A 1999 Cortecs shares hit as drug for osteoporosis flops. Dly Telegr May 26, 1999, p. 1461.
  • 27
    Leone-Bay A, Wang E, Sarubbi D, Leipold H 1999 Compounds and compositions for delivering active agents. US patent 5990166.
  • 28
    Leone-Bay A, Paton DR, Weidner JJ 2000 The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev 20:169186.
  • 29
    Stoll BR, Leipold HR, Milstein S, Edwards DA 2000 A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics. J Control Release 64:217228.
  • 30
    Overgaard K, Christiansen C 1996 A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tissue Int 59:1216.
  • 31
    Gibaldi M, Perrier D 1982 Pharmacokinetics, 1st ed. Marcel Dekker, Inc., New York, NY, USA, pp. 409449.
  • 32
    Beveridge T, Niederer W, Nüesch E, Petrin A 1976 Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). Z Gastroent 10:1215.
  • 33
    Huwyler R, Born W, Ohnhaus EE, Fischer JA 1979 Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am J Physiol 5:1519.
  • 34
    Ardaillou R, Paillard F, Sraer J, Vallée G 1973 Compared kinetics of salmon and human radioiodinated calcitonins in man. Horm Metab Res 5:232233.
  • 35
    Nüesch E, Schmidt R 1981 Comparative pharmacokinetics of calcitonins. In: Pecile A (ed.) Calcitonin 1980, Proceedings of an International Symposium, Milan. Excerpta Medica, Amsterdam, The Netherlands, pp. 352364.
  • 36
    Concia E, Cruciani M, Bartucci F, Arrigoni L, Longoni A 1994 Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose. Eur J Clin Pharmacol 46:371373.
  • 37
    Christgau S 2000 Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin Chem 46:431.
  • 38
    Schlemmer A, Hassager C 1999 Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140:332337.
  • 39
    Abbiati G, Arrigoni M, Frignani S, Longoni A, Bartucci F, Castiglioni C 1994 Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers. Calcif Tissue Int 55:346348.
  • 40
    Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG 1996 The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 58:216220.
  • 41
    Ongphiphadhanakul B, Piaseu N, Chailurkit L, Rajatanavin R 1998 Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcif Tissue Int 62:379382.
  • 42
    Singer FR, Melvin KEW, Mills BG 1976 Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol 5:333340.
  • 43
    Ardaillou R, Vuagnat P, Milhaud G, Richet G 1967 Effets de la thyrocalcitonine sur l'excrétion rénale des phosphates, du calcium et des ions H+ chez l'homme. Nephron 4:298314.
  • 44
    Haas HG, Dambacher MA, Guncaga J, Lauffenburger T 1971 Renal effects of calcitonin and parathyroid extract in man. J Clin Invest 50:26892702.
  • 45
    Cochran M, Peacock M, Sachs G, Nordin BEC 1970 Renal effects of calcitonin. BMJ 1:135137.
  • 46
    Paillard F, Ardaillou R, Malendin H, Fillastre JP, Prier S 1972 Renal effects of salmon calcitonin in man. J Lab Clin Med 80:200216.
  • 47
    Overgaard K 1994 Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 55:8286.
  • 48
    Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M 1995 Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin : a prospective study. Calcif Tissue Int 56:181185.
  • 49
    NIH Consensus Development Panel on Osteoporosis Prevention 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785795.